Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The UK company buys IRDx for $1bn.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
